YF Life Launches New “TaxVantage PrimeChoice Medical Plan" Incorporating Advanced Histotripsy Technology into Coverage

Offering Clients More Medical Options on Their Healthcare Journey

July 14, 2025

YF Life Insurance International Limited (YF Life) is proud to announce the launch of its new Voluntary Health Insurance Scheme (VHIS) Flexi Plan, "TaxVantage PrimeChoice Medical Plan". This plan offers clients with annual benefit limit up to HK$2,000,000, with no lifetime benefit limit. It offers coverage for unknown pre-existing conditions without any waiting period and includes a “No Claim Premium Discount”, demonstrating YF Life’s unwavering commitment to clients’ health protection. Concurrently, YF Life is incorporating the advanced Histotripsy Technology into the coverage scope of its designated medical plans¹. This move fully embody YF Life’s vision to encompass the latest medical technologies within its coverage, thereby enhancing the level of health protection for its clients.

The “TaxVantage PrimeChoice Medical Plan” offers extensive protection for hospitalization, surgical procedures, day case treatments, and various treatments. Beyond basic medical protection, clients can also flexibly choose additional supplementary benefits based on their individual or family needs for more extensive coverage. The plan’s scope even covers advanced Histotripsy technology, providing clients with more choices on their healthcare journey.

Furthermore, liver cancer is one of the top five common cancers in Hong Kong. In 2022, based on crude annual incidence rates, there were 22 new cases per 100,000 population in Hong Kong ², and the mortality rate is also relatively high. In August last year, the Li Ka Shing Foundation introduced Histotripsy technology to Hong Kong. This technology uses high-intensity ultrasound waves to precisely disrupt cancer tissues, offering a non-invasive, painless, and highly effective treatment option for liver cancer patients, and bringing them a ray of hope. Compared to traditional treatment methods, Histotripsy treatment typically involves fewer side effects and complications, and patients can generally be discharged the day after treatment, greatly enhancing recovery efficiency³.

As the first private hospital in Asia to adopt the Histotripsy system, Gleneagles Hospital Hong Kong (Gleneagles) has already begun providing this treatment to liver cancer patients. YF Life not only expands the coverage of its designated medical plans1 to include this advanced technology but also provides Cashless Arrangement Service, covering hospitals such as Gleneagles and other partner institutions⁴, through its user-friendly "YF GO!” one-stop value-added service platform. This thoughtful arrangement allows clients to receive treatment with greater peace of mind, helping to reduce the financial burden of high medical costs, once again reaffirming YF Life’s "people-centric" core value and its steadfast commitment to standing by its clients and safeguarding their health.

Remarks:

1. Designated medical plans include: Hospital & Surgical Plus, E+ Medicare, TaxVantage Medical Plan、TaxVantage Plus Medical Plan, TaxVantage Prestige Medical Plan, TaxVantage PrimeChoice Medical Plan, Prestige MediCare, Supreme MediCare, VIP Global MediCare, and VIP Worldwide MediCare.

2. Please refer to Cancer Online Resource Hub for details: https://www.cancer.gov.hk/en/hong_kong_cancer/common_cancers_in_hong_kong/liver_cancer.html

3. Refers to the relevant information from The University of Hong Kong: https://www.hku.hk/press/press-releases/detail/27630.html

4. The three private hospitals providing Histotripsy treatment are all eligible hospitals under YF GO!’s Cashless Arrangement Service. They are Gleneagles Hospital Hong Kong, CUHK Medical Centre and Hong Kong Sanatorium & Hospital.

Any promotional offer(s) or materials(s) should be read in conjunction with the relevant product brochure and terms and conditions. Customers should not apply for the relevant insurance product(s) solely on the basis of the above information. This press release contains general information only. It shall not be constructed as an offer to sell any product. Although care is taken in preparing the above information, YF Life disclaims any express or implied warranty as to the accuracy of the content and any liability with respect to it. In the event of any conflict or inconsistency between the contents of the above information and the relevant policy contracts, the relevant policy contract shall prevail. The information contained in this press release is intended as a general summary of information for reference only. For more details, please refer to relevant product brochures, promotion leaflets, and policy documents. For the details of the relevant product, the terms and conditions of the policy shall prevail.

This press release is intended for distribution in Hong Kong only and should not be construed as an offer or solicitation to sell or promote any YF Life products outside Hong Kong. YF Life declares that it has no intention to offer to sell, to solicit to buy or to provide any of its products in any jurisdiction other than Hong Kong in which such offer to sell or solicitation to buy or provision of any product of YF Life is illegal under the laws of that jurisdiction.